SCHEMBL4594974

SCHEMBL4594974

S=C1[N]C=CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1690923 0.62
Hydrochloric Acid SCHEMBL3861041 0.61
SCHEMBL11422204 0.59
SCHEMBL125053 0.29
SCHEMBL31203085 0.29
Methane SCHEMBL23044967 0.25
SCHEMBL6559802 0.25
SCHEMBL7642788 0.25
SCHEMBL19728 0.25
SCHEMBL2685201 0.25

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1646584-A1 REDUCTION OF THE CONCENTRATION OF UNDESIRED COMPOUNDS Ineos Fluor Holdings Limited (GB) 2006-04-19 EP claimed
WO-2005012178-A1 REDUCTION OF THE CONCENTRATION OF UNDESIRED COMPOUNDS INEOS FLUOR HOLDINGS LIMITED (GB) 2005-02-10 WO claimed
EP-1983982-A1 DRUG COMBINATIONS BIAL - Portela & Ca., S.A. (PT) 2008-10-29 EP disclosed
EP-1957112-A2 ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE Sanna, Pietro Paolo (US) 2008-08-20 EP disclosed
WO-2007081232-A1 DRUG COMBINATIONS BIAL- PORTELA & CA, S.A. (PT) 2007-07-19 WO disclosed
WO-2007062048-A2 ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE SCRIPPS RESEARCH INST (US) 2007-05-31 WO disclosed
EP-1646584-A1 REDUCTION OF THE CONCENTRATION OF UNDESIRED COMPOUNDS Ineos Fluor Holdings Limited (GB) 2006-04-19 EP disclosed
EP-1543017-A2 BIFUNCTIONAL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME Rib-X Pharmaceuticals, Inc. (US) 2005-06-22 EP disclosed
EP-1507767-A1 4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL-2-ONES AS AGONISTS OF THE ALPHA-2B AND ALPHA-2C ADRENERGIC RECEPTORS Allergan, Inc. (US) 2005-02-23 EP disclosed
WO-2005012178-A1 REDUCTION OF THE CONCENTRATION OF UNDESIRED COMPOUNDS INEOS FLUOR HOLDINGS LIMITED (GB) 2005-02-10 WO disclosed
WO-2004029066-A2 BIFUNCTIONAL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME RIB-X PHARMACEUTICALS, INC. (US) 2004-04-08 WO disclosed
US-5719280-A REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID SYNTEX (U.S.A.) INC. (US) 1998-02-17 US disclosed
CN-1151735-A Benzocycloalkylazolethione derivatives SYNTEX INC (US) 1997-06-11 CN disclosed
EP-0757677-A1 BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES SYNTEX (U.S.A.) INC. (US) 1997-02-12 EP disclosed
EP-0757677-A1 BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES SYNTEX (U.S.A.) INC. (US) 1997-02-12 EP disclosed
US-5538988-A CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS SYNTEX (U.S.A.) INC. 1996-07-23 US disclosed
US-5538988-A CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS SYNTEX (U.S.A.) INC. 1996-07-23 US disclosed
WO-1995029165-A3 BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS SYNTEX INC (US) 1995-12-07 WO disclosed
WO-1995029165-A2 BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1995-11-02 WO disclosed
WO-1995029165-A2 BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1995-11-02 WO disclosed